P1vital Products Limited have developed a technology that has the potential to reduce the amount of time it takes to detect whether a patient is responding to a particular antidepressant medication.

The technology is called the PReDicT Test, and has been shown in early tests to be able to predict whether a patient is responding (with 75% accuracy) after only 7—10 days of starting antidepressant medication; current approaches to detecting treatment response (using questionnaire measures available to GPs) take between 4—6 weeks. More information about the PReDicT Test technology is available here

MindTech are working with P1vital Ltd to trial the computer-based technology as part of care. The study is an international trial taking place in five European countries (UK, France, Germany, Netherlands and Spain), co-funded by the European Commission’s Horizon 2020 EU Framework Programme for Research and Innovation. The trial is a collaboration between industry, healthcare and academia and a list of partners is given below. The trial is being run within primary care, and patients at participating practices are invited to join the study if they are being prescribed an antidepressant by their GP or alternative clinician (depending on how care is structured within that county). The trial will compare the outcomes of patients treated using the PReDicT Test to those receiving treatment as usual, to see whether more patients show a response to treatment after 8 weeks using the PReDicT Test. It will also compare the extent of improvement in patients across both groups.  You can read more about the study here. The study has been recruiting since 2016, and will cease recruitment in November 2018. 

MindTech’s particular role in the trial is to explore the acceptability of the technology amongst patients and clinicians, and also how it sits alongside existing care processes and practices.  In addition to this, work carried out by research partners in Oxford will examine the cost effectiveness of its use. The study will provide valuable evidence of its potential use in primary care treatment for depression.

Partners involved in the study are:

  • P1Vital Products Limited
  • University of Oxford, Health Economics Research Centre
  • University of Nottingham, MindTech
  • Hospital Sainte-Anne, Paris Descartes University
  • Universitätsklinikum Würzburg
  • Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at University Hospital Frankfurt
  • Parc de Salut Mar, and Hospital del Mar Medical Research Institute (IMIM), Barcelona; Biomedical Research Networking Center for Mental Health Network (CIBERSAM)
  • VU University Medical Centre Amsterdam
  • Universitair Centrum Psychiatrie (UMCG), Netherlands and GGZ ingest, Netherlands

For further information about MindTech’s role in this study, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.